Economic Atlas
Home
Screener
Chat
Companies
More
Economic Atlas
Companies
/
Werewolf Therapeutics, Inc.
+ Follow company
Company profile
Werewolf Therapeutics, Inc.
NASDAQ: HOWL · Healthcare · Biotechnology
Public
HQ Watertown, MA · Middlesex
CIK 0001785530
Reports USD
#1 of 1,394 Healthcare companies by revenue
EA Score
—
—
FH
30
DQ
—
GM
—
SS
40
v0.1 · 35/100 weight · pillars only
↑ filing timeliness, market scale · ↓ return on equity, listing tenure
Methodology →
Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$60.8M
Employees
46
Market cap
$16.5M
Overview
Financials
Segments
Filings
ESG
People & Places
Financials — latest annual
SEC EDGAR · USD-normalized
Concept
USD
Native
FY
Net income
-$60.8M
-$60.8M
2025
Operating income
-$60.7M
-$60.7M
2025
Total assets
$69.4M
$69.4M
2025
Liabilities
$44.6M
$44.6M
2025
Equity
$24.8M
$24.8M
2025
Revenue by segment
Filed disclosures · FY2024
Cite
Export
By product
Reportable
100%
By geography
Not disclosed.
The read
Werewolf Therapeutics, Inc. earned -$60.8M in FY2025 net income.
Peers · Healthcare
Pelthos Therapeutics Inc.
35
D
Voyageur Pharmaceuticals Ltd.
—
—
Selectis Health, Inc.
61
C
Zenith Capital Corp.
—
—
Neighbors
Middlesex →
GE Vernova Inc.
$38.1B
63
C
Thermo Fisher Scientific Inc.
$44.6B
86
A
Analog Devices, Inc.
$11.0B
87
A
The TJX Companies, Inc.
$60.4B
85
A
Boston Scientific Corporation
$20.1B
88
A
Alnylam Pharmaceuticals, Inc.
$3.7B
79
B+
Key facts
CEO
Daniel J. Hicklin
Sector
Healthcare
Industry
Biotechnology
Headquarters
Watertown, MA
Exchange
NASDAQ: HOWL
Employees
46
IPO date
2021-04-30
Latest filings
8-K
2026-05-07
10-Q
2026-05-07
10-K
2026-03-27
8-K
2026-03-27
8-K
2026-02-24
8-K
2026-02-13
8-K
2026-02-06
8-K
2025-12-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.
Home
Screener
Chat
Companies
More